Key Takeaway: Lantheus reported its financial results for the second quarter of 2026, revealing worldwide revenue of $388.2 million. The GAAP fully diluted earnings per share were $1.11, slightly down from $1.12 in the same quarter of 2025. Adjusted fully diluted earnings per share also decreased to $1.55 from $1.57 year-over-year.
Price reaction · baseline $101.5 (2026-08-05 close) · hit pre-market · 1 other LNTH headline(s) in the window, move may be shared
day 0 close · peak
-0.4%
Market Sentiment Analysis
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+48%
120-day peak, hindsight
Typical move
2%
average across 7 past catalysts
Lead asset
18F-DCFPyL
Phase 3 · Prostate Cancer
Full Press Release Details
Worldwide revenue of $388.2 million in the second quarter of 2026 GAAP fully diluted earnings per share of $1.11, compared to $1.12 in the second quarter of 2025 Adjusted fully diluted earnings per share of $1.55, compared to $1.57 in the second quarter of 2025 Announced on August 3, 2026 that it
The post Lantheus Reports Second Quarter 2026 Financial Results appeared first on Lantheus .
Frequently Asked Questions
What was Lantheus' revenue for Q2 2026?
Lantheus reported worldwide revenue of $388.2 million for Q2 2026.
How did Lantheus' earnings per share change?
GAAP fully diluted earnings per share were $1.11, down from $1.12 in Q2 2025.
What were the adjusted earnings per share for Lantheus?
Adjusted fully diluted earnings per share were $1.55, compared to $1.57 in Q2 2025.